bioAffinity Technologies vs OmniAb
OmniAb reported revenue of $19 million in fiscal 2025, 3.0 times bioAffinity Technologies' $6 million in fiscal 2025. bioAffinity Technologies' revenue fell 34.2% in its latest year, and OmniAb's fell 29.3%. bioAffinity Technologies had an operating margin of -171.6%, against -369.5% at OmniAb. Free cash flow was −$9 million at bioAffinity Technologies and −$37 million at OmniAb.
Side by side
| bioAffinity Technologies | OmniAb | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6M | $19M |
| Revenue growth | −34.2% | −29.3% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −171.6% | −369.5% |
| Net margin | −242.0% | −347.0% |
| Free cash flow | −$9M | −$37M |
| Free cash flow margin | −152.4% | −198.3% |
| Return on capital | −400.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 325.8% | 11.0% |
| Last close | $1.85 | $5.03 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.0 million, sold $1.2 million | sold $283,037 |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
bioAffinity TechnologiesOmniAb
Operating margin
Percent of revenue
bioAffinity TechnologiesOmniAb
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
bioAffinity TechnologiesOmniAb
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the bioAffinity Technologies and OmniAb pages.